Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.
Uher T, McComb M, Galkin S, Srpova B, Oechtering J, Barro C, Tyblova M, Bergsland N, Krasensky J, Dwyer M, Havrdova EK, Posova H, Vaneckova M, Zivadinov R, Horakova D, Kuhle J, Ramanathan M. Uher T, et al. Among authors: tyblova m. Mult Scler. 2021 Feb;27(2):220-231. doi: 10.1177/1352458520912379. Epub 2020 Apr 7. Mult Scler. 2021. PMID: 32255388
Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score.
De Jager PL, Chibnik LB, Cui J, Reischl J, Lehr S, Simon KC, Aubin C, Bauer D, Heubach JF, Sandbrink R, Tyblova M, Lelkova P; Steering committee of the BENEFIT study; Steering committee of the BEYOND study; Steering committee of the LTF study; Steering committee of the CCR1 study; Havrdova E, Pohl C, Horakova D, Ascherio A, Hafler DA, Karlson EW. De Jager PL, et al. Among authors: tyblova m. Lancet Neurol. 2009 Dec;8(12):1111-9. doi: 10.1016/S1474-4422(09)70275-3. Epub 2009 Oct 29. Lancet Neurol. 2009. PMID: 19879194 Free PMC article.
HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event.
Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Tamaño-Blanco M, Tyblova M, Hussein S, Bergsland N, Willis L, Krasensky J, Vaneckova M, Seidl Z, Lelkova P, Ramanathan M. Horakova D, et al. Among authors: tyblova m. J Neuroimmunol. 2011 Jul;236(1-2):76-80. doi: 10.1016/j.jneuroim.2011.04.011. Epub 2011 May 31. J Neuroimmunol. 2011. PMID: 21621859 Clinical Trial.
Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study.
Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Qu J, Tamaño-Blanco M, Badgett D, Tyblova M, Bergsland N, Hussein S, Willis L, Krasensky J, Vaneckova M, Seidl Z, Lelkova P, Dwyer MG, Zhang M, Yu H, Duan X, Kalincik T, Ramanathan M. Horakova D, et al. Among authors: tyblova m. PLoS One. 2013;8(1):e53996. doi: 10.1371/journal.pone.0053996. Epub 2013 Jan 8. PLoS One. 2013. PMID: 23320113 Free PMC article. Clinical Trial.
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.
Weinstock-Guttman B, Zivadinov R, Horakova D, Havrdova E, Qu J, Shyh G, Lakota E, O'Connor K, Badgett D, Tamaño-Blanco M, Tyblova M, Hussein S, Bergsland N, Willis L, Krasensky J, Vaneckova M, Seidl Z, Ramanathan M. Weinstock-Guttman B, et al. Among authors: tyblova m. J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1186-91. doi: 10.1136/jnnp-2012-304740. Epub 2013 Apr 17. J Neurol Neurosurg Psychiatry. 2013. PMID: 23595944
56 results